Trial Profile
Multicenter, Open Label, Single Arm, Prospective, Phase IV Study to Evaluate the Safety and Efficacy of MyHep AllTM (sofosbuvir/ velpatasvir, Fixed Dose Combination) in Adult Indian Patients who have Chronic Hepatitis C Virus (HCV) Infection - NIL
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2018
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Mylan Laboratories Limited
- 13 Nov 2018 New trial record
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.